NCI ETCTN Pittsburgh Cancer Consortium (PCC)

NCI ETCTN 匹兹堡癌症联盟 (PCC)

基本信息

批准号：
10784844
负责人：
Jan Hendrik Beumer
金额：
$ 61.17万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-25 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10784844
关键词：
Acceleration Adult Albert Einstein Cancer Center Antineoplastic Agents Biological Markers Cancer Center Cancer Patient Cancer Therapy Evaluation Program Catchment Area Characteristics Clinical Clinical Drug Development Clinical Trials Clinical Trials Network Comprehensive Cancer Center Conduct Clinical Trials Development Drug Kinetics Early Therapeutic-Clinical Trials Network Enrollment Florida Goals Health Infrastructure Institution Investigation Investigational Therapies Lead Leadership Malignant Neoplasms Mission Molecular National Cancer Institute Patients Pennsylvania Pharmaceutical Preparations Phase Phase II Clinical Trials Process Productivity Program Development Regimen Series Therapeutic Agents Toxic effect Universities University of Pittsburgh Cancer Institute Work anticancer research appropriate dose cancer care cancer therapy clinical development drug development early phase clinical trial experience interest member novel novel therapeutics phase I trial phase II trial programs response tumor

项目摘要

Abstract For more than 40 years, the National Cancer Institute (NCI) has supported an infrastructure program to conduct clinical trials across the US. To enhance, facilitate, and expedite the process of early-phase drug development, the NCI implemented a comprehensive plan transforming the NCI-sponsored early-phase clinical trials program from a series of separate institutions and efforts to a new, consolidated, integrated program, referred to as the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). The UPMC Hillman Cancer Center (formerly the University of Pittsburgh Cancer Institute, hereafter referred to as ‘HCC’) has been an NCI-designated comprehensive cancer center since 1990, and has been involved in the NCI Early Drug Development Program since 1999. Our group was one of 12 academic centers to be selected as an ETCTN Lead Academic Organization (LAO) for the phase 1 component, and subsequently selected as one of 10 academic centers to integrate phase 2 clinical trial efforts, with responsibility for developing, leading, and accruing to ETCTN clinical trials for adult cancer patients. We now propose to be a member of the NCI ETCTN as the Pittsburgh Cancer Consortium (PCC) Lead Academic Organization in a consortium with the University of Florida Health Cancer Center and the Albert Einstein Cancer Center. The goal of the PCC is to create a unified, integrated clinical trials network that will allow for more seamless advancement and progress of novel experimental agents and/or combinations through early stages of drug development. The eventual goal of our program is to greatly facilitate and accelerate the delivery of new cancer therapies to the citizens of Pennsylvania, North-Central Florida, Bronx, NY, and their respective catchment areas.

抽象的 40 多年来，美国国家癌症研究所 (NCI) 一直支持基础设施建设计划在美国各地进行临床试验，以加强、促进和加快这一过程。在早期药物开发阶段，NCI 实施了一项全面计划，转变 NCI 赞助的早期临床试验计划，来自一系列独立的机构和努力一项新的综合性计划，称为 NCI 实验疗法临床试验网络 (ETCTN)。 UPMC 希尔曼癌症中心（前身为 UPMC 大学）。匹兹堡癌症研究所（以下简称“HCC”）已被 NCI 指定为自1990年起担任综合癌症中心，并参与NCI早期药物研究自1999年以来的发展计划。我们组是被选为“发展计划”的12个学术中心之一 ETCTN 牵头学术组织 (LAO) 负责第一阶段的工作，随后被选为 10 个整合 2 期临床试验工作的学术中心之一，并承担责任我们现在致力于为成年癌症患者开发、领导和积累 ETCTN 临床试验。提议成为 NCI ETCTN 成员，担任匹兹堡癌症联盟 (PCC) 负责人与佛罗里达大学健康癌症中心联合成立的学术组织阿尔伯特·爱因斯坦癌症中心的目标是创建一个统一、综合的临床中心。试验网络将允许新的实验更加无缝地推进和进展药物开发的早期阶段的药物和/或组合是我们的最终目标。该计划旨在极大地促进和加速向公民提供新的癌症疗法宾夕法尼亚州、佛罗里达州中北部、纽约州布朗克斯及其各自的集水区。